Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
StateHouse Holdings Inc. (STHZF)
San Diego, CA, US
StateHouse Holdings Inc. operates as a vertically integrated enterprise within the U.S. cannabis sector, encompassing cultivation, processing, manufacturing, distribution, and direct retail sales of its products. The company caters to both the adult recreational and medical cannabis markets. Its retail network comprises 13 dispensaries throughout California, along with one location in Oregon, including a notable outlet situated in San Francisco's iconic Haight Ashbury district. This organization, previously known as Harborside Inc., rebranded to StateHouse Holdings Inc. in July 2022. Its corporate headquarters are located in San Diego, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -90.00% | -90.00% | -90.00% | -50.00% | +9,900.00% | -99.33% | -99.75% | -99.99% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-5.4% Q2'24: +8.2% (vs Q2'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+81.7% ★ Q2'24: +108.2% (vs Q2'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-46.3% Q2'24: -0.8% (vs Q2'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-11.9% Q2'24: +12.4% (vs Q2'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q2'24: -22.2% (vs Q2'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+18.5% Q2'24: +15.8% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-41.32× Q2'24: 6.89× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
516.9K
est: 41.03M (-98.7%)
|
47.34M
est: 41.03M (+15.4%)
|
63.12M
est: 47.14M (+33.9%)
|
59.77M
est: 49.21M (+21.5%)
|
108.25M
est: 82.73M (+30.8%)
|
102.39M
est: 76.75M (+33.4%)
|
68.61M
est.
|
81.80M
est.
|
86.11M
86.11M – 86.11M
+5.3% YoY
|
| EBITDA |
-3.31M
est: -2.38M (-39.1%)
|
-14.33M
est: -2.38M (-502.9%)
|
4.93M
est: -2.73M (+280.3%)
|
-846.5K
est: -2.85M (+70.3%)
|
-1.85M
est: -4.79M (+61.4%)
|
-3.46M
est: -4.45M (+22.3%)
|
-3.98M
est.
|
-4.74M
est.
|
-4.99M
-4.99M – -4.99M
-5.3% YoY
|
| EBIT |
-4.48M
est: -5.39M (+16.9%)
|
-16.82M
est: -5.39M (-211.9%)
|
1.91M
est: -6.20M (+130.8%)
|
-5.08M
est: -6.47M (+21.5%)
|
-13.86M
est: -10.87M (-27.4%)
|
-12.20M
est: -10.09M (-21.0%)
|
-9.02M
est.
|
-10.75M
est.
|
-11.32M
-11.32M – -11.32M
-5.3% YoY
|
| Net Income |
-4.81M
est: -173.27M (+97.2%)
|
-49.46M
est: -173.27M (+71.5%)
|
-11.95M
est: -63.99M (+81.3%)
|
-26.16M
est: 2.50M (-1,147.3%)
|
-233.21M
est: -71.25M (-227.3%)
|
-49.88M
est: -38.43M (-29.8%)
|
-23.60M
est.
|
-24.73M
est.
|
-22.16M
-22.16M – -22.16M
+10.4% YoY
|
| SGA |
2.89M
est: 20.65M (-86.0%)
|
30.44M
est: 20.65M (+47.4%)
|
26.99M
est: 23.73M (+13.7%)
|
27.88M
est: 24.77M (+12.6%)
|
56.13M
est: 41.65M (+34.8%)
|
47.22M
est: 38.63M (+22.2%)
|
34.54M
est.
|
41.18M
est.
|
43.35M
43.35M – 43.35M
+5.3% YoY
|
| EPS |
-0.08
est: -0.68 (+88.1%)
|
-1.49
est: -0.68 (-117.9%)
|
-0.28
est: -0.25 (-10.9%)
|
-0.38
est: 0.01 (-3,954.7%)
|
-1.09
est: -0.28 (-287.6%)
|
-0.20
est: -0.15 (-31.9%)
|
-0.09
est.
|
-0.10
est.
|
-0.09
-0.09 – -0.09
+10.4% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Edward Schmults | Chief Executive Officer & Director | 338.8K | male |
| Kavi Bhai | Chief Financial Officer | 279.5K | male |
| John H. Nichols | General Counsel | 238.1K | male |
| Robert Bacchi | Chief Technology Officer | 217.0K | male |
| Will Senn | Chief Corporate Development Officer | 204.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for STHZF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
